Current challenges in personalizing warfarin therapy.

Area of Science:

• Pharmacology and Therapeutics
• Clinical Pharmacy
• Genetics and Personalized Medicine

Background:

• Vitamin K antagonists (VKAs), such as warfarin, have been used for over 50 years and remain important oral anticoagulants.
• VKA effectiveness and safety are limited by significant inter- and intra-patient dose-response variability.
• Routine International Normalized Ratio (INR) monitoring is necessary to maintain patients within a narrow therapeutic range, yet time in range is often suboptimal (<60%).

Purpose of the Study:

• To explore personalized strategies for optimizing warfarin therapy.
• To discuss the potential of pharmacogenetic data, vitamin K supplementation, and patient self-management in improving warfarin use.
• To highlight the ongoing need for research to fully realize the benefits of personalized warfarin management.

Main Methods:

• Review of current literature on Vitamin K antagonist (VKA) therapy and novel oral anticoagulants.
• Discussion of personalized approaches including pharmacogenetics, vitamin K management, and patient self-testing.
• Consideration of ongoing clinical trials investigating pharmacogenetic testing for warfarin initiation.

Main Results:

• Personalized approaches have the potential to improve warfarin's safety, efficacy, and ease of use.
• No randomized trials have yet proven the benefits of routine pharmacogenetic testing for warfarin initiation.
• Pivotal trials are currently underway to further investigate these personalized strategies.

Conclusions:

• Warfarin, despite the emergence of novel anticoagulants, is likely to remain a key therapeutic option.
• Personalized warfarin management strategies hold promise for enhancing patient outcomes.
• Further research is essential to validate and integrate these personalized approaches into clinical practice.